Results 51 to 60 of about 9,102 (179)

CYP2B6 and Bupropion’s Smoking-Cessation Pharmacology: The Role of Hydroxybupropion [PDF]

Clinical Pharmacology & Therapeutics, 2012
Bupropion is indicated to promote smoking cessation. Animal studies suggest that the pharmacologic activity of bupropion can be mediated by its major metabolite, hydroxybupropion. We measured plasma bupropion and its metabolite levels in a double-blind, placebo controlled, randomized smoking-cessation trial.
Zhu, AZX, Cox, LS, Nollen, N, Faseru, B, Okuyemi, KS, Ahluwalia, JS, Benowitz, NL, Tyndale, RF   +7 more
openaire   +4 more sources

Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Chronic inflammation has long been known to downregulate the activity of certain cytochrome P450 (CYP) enzymes—the main enzymes responsible for the phase I metabolism of many small molecule drugs—potentially leading to higher exposures in patients with chronic inflammatory diseases compared to healthy volunteers. Neglecting this potential difference in
Johannes Tillil, Sathej Gopalakrishnan, Jennifer Dong, Karthik Venkatakrishnan, Charlotte Kloft, Wilhelm Huisinga, Lena Klopp‐Schulze   +6 more
wiley   +1 more source

Long‐Read Pan‐Cancer Transcriptomics Unravel Distinct Alteration Trends Between Gene and Isoform Expression in Tumorigenesis

iMetaMed, EarlyView.
Long‐read profiling of 144 tumor‐normal pairs identifies isoform‐level cancer dysregulation independent of gene changes. Our scoring system prioritizes isoform‐driven prognostic genes across cancers. ABSTRACT Tumorigenesis involves transcriptomic alterations at both gene and isoform levels.
Yuying Ding, Bo Wu, Dan Zhou, Qiang Li, Dingru Li, Mengyun Cai, Zhiyan Chen, Caimei Zhong, ChuanLe Xiao, Yuhua Deng   +9 more
wiley   +1 more source

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog [PDF]

International Journal of Molecular Sciences, 2018
The over two dozen CYP2B structures of human, rabbit, and woodrat enzymes solved in the last decade have significantly enhanced our understanding of the structure-function relationships of drug metabolizing enzymes. More recently, an important role has emerged for halogen-π interactions in the CYP2B6 active site in substrate selectivity, explaining in ...
Shah, Manish B., Zhang, Qinghai, Halpert, James R.   +2 more
openaire   +2 more sources

Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction

Neuroprotection, EarlyView.
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Guoliang Zhu, Xiaoling Chen, Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, Yapeng Lin, Jie Yang   +7 more
wiley   +1 more source

The Efficacy of Cyclophosphamide Combined with Prednisone in Membranous Nephropathy Patients with Different Cytochrome P450 2B6 Gene Polymorphisms and Analysis of Factors Influencing the Efficacy

Drug Design, Development and Therapy, 2022
Min Zhang,1 Yao Lv,2 Haokui Liu3 1Department of Nephrology, Bayannur Hospital, Bayannur, Inner Mongolia, People’s Republic of China; 2Department of Orthopedics, the Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, People ...
Zhang M, Lv Y, Liu H
doaj  

Pharmacogenetics of Cytochrome P450 2B6 (CYP2B6): Advances on Polymorphisms, Mechanisms, and Clinical Relevance

Frontiers in Genetics, 2013
Cytochrome P450 2B6 (CYP2B6) belongs to the minor drug metabolizing P450s in human liver. Expression is highly variable both between individuals and within individuals, owing to nongenetic factors, genetic polymorphisms, inducibility and irreversible ...
Ulrich M Zanger, Kathrin eKlein
doaj   +1 more source

Characterization of CYP2B6 in a CYP2B6-Humanized Mouse Model: Inducibility in the Liver by Phenobarbital and Dexamethasone and Role in Nicotine Metabolism In Vivo [PDF]

Drug Metabolism and Disposition, 2015
The aim of this study was to further characterize the expression and function of human CYP2B6 in a recently generated CYP2A13/2B6/2F1-transgenic (TG) mouse model, in which CYP2B6 is expressed selectively in the liver. The inducibility of CYP2B6 by phenobarbital (PB) and dexamethasone (DEX), known inducers of CYP2B6 in human liver, was examined in the ...
Zhihua, Liu, Lei, Li, Hong, Wu, Jing, Hu, Jun, Ma, Qing-Yu, Zhang, Xinxin, Ding   +6 more
openaire   +2 more sources

Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

Phytotherapy Research, EarlyView.
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit, Aylin Bülbül, Betul Kocaadam‐Bozkurt, Osman Bozkurt, Duygu Ağagündüz, Raffaele Capasso   +5 more
wiley   +1 more source

Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid

Southern African Journal of HIV Medicine
Background: CYP2B6 slow metabolisers have higher efavirenz concentrations, which are further increased by isoniazid inhibiting efavirenz’s accessory metabolic pathway.
Jessica Taylor, Gary Maartens, Simiso Sokhela, Nomathemba Chandiwana, Godspower Akpomiemie, Francois Venter, Phumla Sinxadi   +6 more
doaj   +1 more source